Divi's Labs Q2 Results Preview: PAT, revenue, EBITDA likely to clinch double-digit growth—Here's what analysts expect

Divi's Labs Q2 FY26 Earnings Preview: Hyderabad-headquartered Divi's Laboratories is set to report its financial results on Friday, November 7. The pharmaceutical company is widely expected to report a strong set of quarterly numbers, with double-digit percentage growth rates in the top and bottom lines.

Analysts expect Divi's Labs to register growth across sectors.

Divi's Labs Q2 FY26 Results Preview: What to expect in top and bottom lines?

Add Zee Business as a Preferred Source

According to Zee Business research, Divi's Laboratories is estimated to register a consolidated net profit of Rs 594 crore for the quarter ended September 30, which translates to a year-on-year increase of 16.4 per cent.

The analysts expect its revenue to grow 12 per cent to Rs 2,618 crore. For the corresponding period a year ago, the drug maker had reported a top line of Rs 2,338 crore.

The drug maker is estimated to register growth to the tune of 9-11 per cent in its generics API, custom synthesis manufacturing and nutraceutical segments, according to the research.

Divi's Labs Q2 | How will the pharma firm fare operationally?

Zee Business analysts peg Divi's Labs' second-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 813 crore, up 13.6 per cent over the year-ago period.

They peg its margin -- a key measure of profitability -- to improve to 31 per cent from 30.62 per cent a year ago.

Divi's Labs shares vs Nifty50 vs Nifty Pharma

On Thursday, the Divi's Labs stock gained 1.3 per cent to close at Rs 6,886.3 apiece on BSE, outperforming a Mumbai market where benchmark indices suffered minor losses for a second straight session.

At the current level, the pharma stock has risen 13.2 per cent so far this year, better than a 7.4 per cent gain and a 5.2 per cent decline in the Nifty50 and Nifty Pharma indices, respectively.